WO1986001508A1 - Opiate antagonists - Google Patents
Opiate antagonists Download PDFInfo
- Publication number
- WO1986001508A1 WO1986001508A1 PCT/AU1985/000200 AU8500200W WO8601508A1 WO 1986001508 A1 WO1986001508 A1 WO 1986001508A1 AU 8500200 W AU8500200 W AU 8500200W WO 8601508 A1 WO8601508 A1 WO 8601508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- general formula
- compound
- group
- opiate
- Prior art date
Links
- 239000003401 opiate antagonist Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 24
- 102000003840 Opioid Receptors Human genes 0.000 claims abstract description 17
- 108090000137 Opioid Receptors Proteins 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 12
- 229940127240 opiate Drugs 0.000 claims abstract description 9
- -1 isoferuloyl group Chemical group 0.000 claims abstract description 8
- 230000003533 narcotic effect Effects 0.000 claims abstract description 7
- 229940035676 analgesics Drugs 0.000 claims abstract description 6
- 239000000730 antalgic agent Substances 0.000 claims abstract description 6
- 231100000331 toxic Toxicity 0.000 claims abstract description 6
- 230000002588 toxic effect Effects 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 235000021539 instant coffee Nutrition 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 8
- 241000533293 Sesbania emerus Species 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims description 4
- QURCVMIEKCOAJU-HWKANZROSA-N Isoferulic acid Natural products COC1=CC=C(\C=C\C(O)=O)C=C1O QURCVMIEKCOAJU-HWKANZROSA-N 0.000 claims description 3
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 2
- TXBPPSLWUNTHII-HWKANZROSA-N (e)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl chloride Chemical compound COC1=CC=C(\C=C\C(Cl)=O)C=C1O TXBPPSLWUNTHII-HWKANZROSA-N 0.000 claims description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- 238000000197 pyrolysis Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 125000004797 2,2,2-trichloroethoxy group Chemical group ClC(CO*)(Cl)Cl 0.000 claims 1
- MOKUYUICRPXHER-UHFFFAOYSA-N feruloylquinic acid Natural products COc1cc(C=CC(=O)OC(=O)C2(O)CC(O)C(O)C(O)C2)ccc1O MOKUYUICRPXHER-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000016213 coffee Nutrition 0.000 abstract description 8
- 235000013353 coffee beverage Nutrition 0.000 abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 240000007154 Coffea arabica Species 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 238000002955 isolation Methods 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 0 CC(CC1)*C[C@]1(C)OO Chemical compound CC(CC1)*C[C@]1(C)OO 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- IHKNVZISLLDMOR-UHFFFAOYSA-N O-Acetylferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1OC(C)=O IHKNVZISLLDMOR-UHFFFAOYSA-N 0.000 description 4
- IHKNVZISLLDMOR-GQCTYLIASA-N O-acetylferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1OC(C)=O IHKNVZISLLDMOR-GQCTYLIASA-N 0.000 description 4
- 235000001368 chlorogenic acid Nutrition 0.000 description 4
- 244000013123 dwarf bean Species 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 3
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 235000021331 green beans Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960004127 naloxone Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- YOMSJEATGXXYPX-UHFFFAOYSA-N 2-methoxy-4-vinylphenol Chemical compound COC1=CC(C=C)=CC=C1O YOMSJEATGXXYPX-UHFFFAOYSA-N 0.000 description 2
- FBTSUTGMWBDAAC-UHFFFAOYSA-N 3,4-Dihydroxystyrene Chemical compound OC1=CC=C(C=C)C=C1O FBTSUTGMWBDAAC-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- OFYVUFITJWRDQM-UHFFFAOYSA-N (2E)-2-[(3-hydroxy-4-methoxyphenyl)methylidene]-3-oxobutanoic acid Chemical compound C(C)(=O)/C(/C(=O)O)=CC1=CC(O)=C(OC)C=C1 OFYVUFITJWRDQM-UHFFFAOYSA-N 0.000 description 1
- GBGHICDYSOMICG-UHFFFAOYSA-N (2E)-2-[(3-hydroxy-4-methoxyphenyl)methylidene]-3-oxobutanoyl chloride Chemical compound C(C)(=O)/C(/C(=O)Cl)=CC1=CC(O)=C(OC)C=C1 GBGHICDYSOMICG-UHFFFAOYSA-N 0.000 description 1
- KPCPQHBDENMEIR-WEVVVXLNSA-N (2E)-2-[(4-hydroxy-3-methoxyphenyl)methylidene]-3-oxobutanoyl chloride Chemical compound COC1=CC(\C=C(/C(C)=O)C(Cl)=O)=CC=C1O KPCPQHBDENMEIR-WEVVVXLNSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- LTSOENFXCPOCHG-GQCTYLIASA-N 4-chloro-6-[[(e)-3-oxobut-1-enyl]amino]-1-n-prop-2-enylbenzene-1,3-disulfonamide Chemical compound CC(=O)\C=C\NC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(=O)(=O)NCC=C LTSOENFXCPOCHG-GQCTYLIASA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- FSZZQGYXVQNPQV-UHFFFAOYSA-N C(=C)C=1C=C(C(=CC1)OC)O.OC=1C=C(C=C)C=CC1O Chemical compound C(=C)C=1C=C(C(=CC1)OC)O.OC=1C=C(C=C)C=CC1O FSZZQGYXVQNPQV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000007460 Coffea arabica Nutrition 0.000 description 1
- 235000002187 Coffea robusta Nutrition 0.000 description 1
- 235000003368 Ilex paraguariensis Nutrition 0.000 description 1
- 244000188472 Ilex paraguariensis Species 0.000 description 1
- YKFRUJSEPGHZFJ-UHFFFAOYSA-N N-trimethylsilylimidazole Chemical compound C[Si](C)(C)N1C=CN=C1 YKFRUJSEPGHZFJ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
Definitions
- This invention relates to the identification and isolation of compounds having opiate receptor binding activity, to the synthesis thereof, and to the use of such compounds as opiate narcotic antagonists.
- R, , R 2 and R_ groups represents a feruloyl or isoferuloyl group of the formula II or III, respectively:
- R.. , R_ and R-. are as defined above.
- Feruloylquinic acids of the general formula IV are known to occur in green coffee beans (Clifford, M.N. , Food Chem. 4, 146-149 (1961) ) .
- Compounds of the general formula I may also be isolated directly from coffee beans which have been roasted, ground and extracted with water and from instant coffee. This process, which includes thes teps of adsorption on an ion exchange resin followed by chromatography to isolate fractions having the desired activity, is described in greater detail below.
- the present invention also provides a process for the preparation of the compounds of the general formula I, above, which process comprises the reaction of quinic- 1,3-lactone (or quinide) of the formula V:
- each R separately represents H or a removable hydroxy protecting group, with a ferulic or isoferulic acid of the formula VI or VII, respectively:
- R. is an acetyl or other hydroxy protecting group, or a reactive derivative thereof, followed by removal of the group R. and, if necessary any hydroxy
- the lactone of the formula V may be prepared from quinic acid by reaction with a condensing agent, for example dicyclohexylcarbodiimide (DCC) , or by other known methods, such as by reaction with gaseous HCl in acetone.
- a condensing agent for example dicyclohexylcarbodiimide (DCC)
- DCC dicyclohexylcarbodiimide
- Removable hydroxy protective groups R may be added by methods known per se in the art.
- acetylferuloylquinides or acetylisoferuloylquinides the acetyl group is removed by brief exposure to methanolic K 2 C0 3-
- the process of the invention involves the reaction of quinic-1,3-lactone of the formula
- R. is an acetyl or other hydroxy protecting group, followed by removal of the group R.. Similarly, the protecting isopropylidene or trichloroethoxy carbonyl groups are removed to give in the cases of VA, VB, and VC, the 1,5, and 4-substituted esters of quinic-l,3-lactone respectively.
- Compounds of the general formula I exhibit significant opiate receptor binding activity, and thus have potential for use as opiate antagonists in reversing the toxic effects of opiate narcotic analgesics such as morphine, for example in the treatment of opiate narcotic overdosage and in the reversal of respiratory depression following the use of narcotics during surgery.
- opiate narcotic analgesics such as morphine
- the present invention therefore also extends to pharmaceutical compositions comprising a compound of the general formula I, together with one or more pharmaceutically acceptable carrier or diluent; as well as to methods of treatment of the conditions outlined above, which comprise administration to a patient of a compound of the general formula I, or a pharmaceutical composition containing a compound of the general formula I.
- GC-MS gas chromatogram-mass spectra
- Principal total ion peaks of the gas chromatogram contained M/Z 249 (derivatized feruloyl ions) and five of these also exhibit the same molecular ion M/Z 566.
- the five, with similar mass spectra, are from the possible feruloylquinides of general formula I. Some may be cis-isomers produced as artifacts by the conditions during gas chromatography.
- Another five hidden peaks of derivatized caffeoyl ions M/Z 307, totalling 10% of the feruloyl ions were also observed and were assumed to represent demethylation that occurred during isolation.
- Conversion of the roasted bean to instant coffee is estimated to double the concentration of active quinides - possibly to 2% of instant coffee. If this figure is applied to - the ED 50 for instant coffee set out in Table 1 (1.2 mg/ml) it would indicate that feruloylquinides have an ED 5Q of 0.024 mg/ml. The finding of 0.05 mg/ml for crude feruloylquinides indicates that one or more of the isomeric forms of feruloylquinide produce the predominant opiate receptor binding activity of instant coffee.
- ED-.'s represent the concentration of material required to displace by 50% the binding of 3 H-naloxone in a crude rat brain membrane preparation as described in detail hereinafter. Samples were dissolved in 0.05 M Tris (HCl buffer at pH 7.4 and assayed in triplicate' at 3 to 5 concentrations. ED-, values are determined graphically on log transformed data.
- Figure 2 shows mass chromatograms of (A) TMS derivatives of instant coffee extract (Fig.l) showing time profiles of total ion current, ions m/z 249 (feruloyl ion), and m/z 566 and (b) TMS derivatives of 4- and 5-caffeoylquinides showing time profiles of total ion current, ion m/z 307 (caffeoyl ion) , and m/z 624 (M+) .
- Derivatives were prepared by reaction of sample with 100 ⁇ l trimethylsilylimidazole (Pierce) and
- the receptor assay system was based on that of Pert and Snyder (Pert, C.B. & Snyder, S.H., Proc. Natu. Acad. Sci. U.S.A. 70, 2243-2247, (1973) ).
- Male Sprague-Dawley rats were killed by decapitation, and brains minus cerebellum homogenized in 25x vol of 0.05 Tris-HCl, pH 7.4 buffer using a Brinkmarin Polytron on setting 4 for 5 s. The homogenate was centrifuged for 20 min at 18,000 g, and the pellet resuspended in 25x vol buffer.
- Acetylferulic acid was prepared after the method of L.S.Fosdick & A.C.Starke, J.Am.Chem.Soc. 6J2, 3352-5 (1940).
- Acetylferuloylquinide from the previous preparation was dissolved in methanol and K ⁇ CO ⁇ dissolved in aq.methanol was added.
- acetylisoferulic acid prepared previously by J.Pacsu and C.Stieber, Ber. 62B, 2974-9 (1929)
- acetylisoferuloylquinides may be prepared exactly as described previously • for acetylferuloylquinides.
- the acetyl group may be removed by the method described previously to yield the 1-feruloyl ester of quinic-1,3-lactone.
- the 1-isoferuloyl ester of quinic-l,3-lactone may be prepared.
- Example 4 The general procedures of Example 4, may be repeated using 2,2,2-trichloroethoxycarboxy esters as protecting groups on the 1-, or 1- and 5-, hydroxy groups of quinic-1,3—lactone, following ' the methods for synthesis and facile hydrolysis described by T.B.Windolz and D.B.R.Johnston, Tetrahedron Lett. 2555 (1967) .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compounds of general formula (I), wherein one of the R1, R2 and R3 groups represents a feruloyl or isoferuloyl group of formula (II) or (III), respectively, and the other R1, R2 and R3 groups represent hydrogen. These compounds have opiate receptor activity and may be used in treatment of the toxic effects of opiate narcotic analgesics. Preparation of these compounds by extraction from coffee, and by synthetic processes is disclosed.
Description
"OPIATE ANTAGONISTS"
This invention relates to the identification and isolation of compounds having opiate receptor binding activity, to the synthesis thereof, and to the use of such compounds as opiate narcotic antagonists.
Previous reports have shown that solutions of instant coffee powders, both normal and decaffeinated, contain ligands for opiate receptors with characteristics similar to those of known opiate antagonists such as naloxone (Boublik, J.H. et al. Nature 301, 246-248 (1983) ). Further work has now enabled the isolation of the principal component of this opiate receptor binding activity and established the identity thereof.
According to the present invention there are provided compounds having opiate receptor binding activity of the general formula I
OR,
wherein one of the R, , R2 and R_ groups represents a feruloyl or isoferuloyl group of the formula II or III, respectively:
and
and the other R, , R~ and R., groups represent hydrogen.
Compounds of the general formula' I above may be derived by pyrolysis from the corresponding feruloylquinic acids of the general formula IV
Feruloylquinic acids of the general formula IV are known to occur in green coffee beans (Clifford, M.N. , Food Chem. 4, 146-149 (1961) ) .
Compounds of the general formula I may also be isolated directly from coffee beans which have been roasted, ground and extracted with water and from instant coffee. This process, which includes thes teps of adsorption on an ion exchange resin followed by chromatography to isolate fractions having the desired activity, is described in greater detail below.
The present invention also provides a process for the preparation of the compounds of the general formula I, above, which process comprises the reaction of quinic- 1,3-lactone (or quinide) of the formula V:
wherein each R separately represents H or a removable hydroxy protecting group, with a ferulic or isoferulic acid of the formula VI or VII, respectively:
wherein R. is an acetyl or other hydroxy protecting group, or a reactive derivative thereof, followed by removal of the group R. and, if necessary any hydroxy
1 4 protecting groups R .
The lactone of the formula V may be prepared from quinic acid by reaction with a condensing agent, for example dicyclohexylcarbodiimide (DCC) , or by other known methods, such as by reaction with gaseous HCl in acetone. Removable hydroxy protective groups R may be added by methods known per se in the art.
In one embodiment of the process of this invention, quinic acid is converted to quinic-1,3-lactone (V) in the presence of DCC,: and then acetyl ferulic acid or acetyl isoferulic acid (VI, VII, R,= CH^CO-) is added. Following the formation of acetylferuloylquinides or acetylisoferuloylquinides, the acetyl group is removed by brief exposure to methanolic K2C03-
Preferably, the process of the invention involves the reaction of quinic-1,3-lactone of the formula
OH with the hydroxyls on carbons 4 and 5 blocked with an isopropylidene group (formula VA) , or the hydroxyl on carbon 1 protected with a 2,2,2-trichloroethoxy carboxy
ester (formula VB) or both hydroxyls 1 and 5 similarly esterified. (formula VC) :
wherein R. is an acetyl or other hydroxy protecting group, followed by removal of the group R.. Similarly, the protecting isopropylidene or trichloroethoxy carbonyl groups are removed to give in the cases of VA, VB, and VC, the 1,5, and 4-substituted esters of quinic-l,3-lactone respectively.
Compounds of the general formula I exhibit significant opiate receptor binding activity, and thus have potential for use as opiate antagonists in
reversing the toxic effects of opiate narcotic analgesics such as morphine, for example in the treatment of opiate narcotic overdosage and in the reversal of respiratory depression following the use of narcotics during surgery.
The present invention therefore also extends to pharmaceutical compositions comprising a compound of the general formula I, together with one or more pharmaceutically acceptable carrier or diluent; as well as to methods of treatment of the conditions outlined above, which comprise administration to a patient of a compound of the general formula I, or a pharmaceutical composition containing a compound of the general formula I.
Preliminary attempts to isolate opiate receptor-active material in instant coffee by solvent extraction and chromatography indicated that activity was associated with yellow pigment having an absorption maximum of 325 nm, which is characteristic of the chlorogenic acids. On silica chromatography, the activity was less polar than the most nonpolar of the chlorogenic acids, i.e. the dicaffeoylquinic acids or "isochlorogenic acid" as isolated from green coffee beans (Sondheimer, E. , Szymanski, CD. & Corse, J. . J. Agr. Food Chem. 9, 146-149 (1961) ). Further, it was non-acidic, being not adsorbed by DEAP-LH20 anion exchanger (acetate-form) in 72% aq. ethanol (Setchell, K.D.R. , Alme, B. , Axelson, M. & Sjovall, J. J.steroid Biochem. 7, 615-629 (1976) ). In common with many of the caffeoylquinic acids, it was prone to oxidation, particularly on silica during chromatography.
Isolation was monitored by an assessment of EDj.,- values in an opiate receptor assay described hereinafter in detail (see Table 1 below) . Fig.l details the chosen isolation scheme which resulted in a twenty-fold increase in specific activity, i.e. from an ED [-n of 1.2 mg/ l for instant coffee to 0.05 mg/ml for the final extract. The GC-MS (gas chromatogram-mass spectra) findings are presented in Fig.2A. Principal total ion peaks of the gas chromatogram contained M/Z 249 (derivatized feruloyl ions) and five of these also exhibit the same molecular ion M/Z 566. The five, with similar mass spectra, are from the possible feruloylquinides of general formula I. Some may be cis-isomers produced as artifacts by the conditions during gas chromatography. Another five hidden peaks of derivatized caffeoyl ions M/Z 307, totalling 10% of the feruloyl ions were also observed and were assumed to represent demethylation that occurred during isolation.
i has been shown (Reichstein, T. Helv. chim.
Acta 15, 1450-1453 (1932) ) that a compound, subsequently called Hauschild's Substance, isolated from the beverage "mate" (Hauschild, . Mitt. Levensmitt. Hyg. 26, 329 (1935) (Chem. Abs. 30, 3537 (1936) ) was a lactone of neochlorogenic acid (5-caffeoylquinic acid) formed during the preparation of the drink from Ilex paraguariensis. In view of the fact that green coffee beans may contain up to 10%, on a dry weight basis, of chlorogenic acids, of which 75% are caffeoylquinic acids (Clifford, supra) , it is highly probable that
Hauschild's Substance, and other caffeoylquinides, would be present in roasted and instant coffee. To test whether these contribute to opiate receptor activity, pure chlorogenic acid, 3-caffeoylquinic acid, isolated
from green coffee beans (Sandheimer et al, supra) was heated to 90°C in saturated NaHC0_ solution for 30 minutes. This is known to produce a mixture of 4- and 5-caffeoylquinic acids (Haslam, E., Makinson, G.K., Naumann, M.O. & Cunningham, J. J.che . Soc. 2137-2146 (1964) ) . The mixed acids were then lactonized by heating to 90°C for 3 hours in glacial acetic acid. Flash chromatography by the same system in Fig.l lead to a product with negligible opiate receptor activity (Table 1). The same product on GC-MS showed two peaks,# presumably 4- and 5-caffeoylquinides (Fig.2B) . Although these probably represent the usually more stable trans isomers and the cis forms still remain to be tested, this is in accordance with the observation (Table 1) that the 3-methyl ether of 3,4-dihydroxystyrene (4-vinylguaiacol) has appreciable opiate receptor binding activity while the unmethylated 'parent compound has none.
It has been noted that opiate receptor activity develops in coffee beans with roasting, and a comparison of the Arabica and Robusta species of coffee shows that the latter can produce a higher level of activity when each is identically roasted, ground, and extracted with hot water (Table 1) . As it is a well documented observation that Robusta green beans contain about twice the level of feruloylquinic acids as Arabica, (Clifford, supra; Rees, D.I. & Theaker, P.D. 8th International Scientific Colloquium on Coffee, Abidjan, 1977, ASIC (Paris) 79-84 (1979) ) , this finding is compatible with the generation of feruloylquinides during roasting and the difference in opiate receptor activity of the two brewed coffees.
Robusta green beans can have a content of up to 2% feruloylquinic acids (Rees et al, supra) , so if it is assumed that instant coffee has been manufactured from beans with a 1.5% content, then, in a "medium" roast (Rees et al, supra) , about two-thirds of this could be dehydrated to feruloylquinides. Conversion of the roasted bean to instant coffee is estimated to double the concentration of active quinides - possibly to 2% of instant coffee. If this figure is applied to - the ED50 for instant coffee set out in Table 1 (1.2 mg/ml) it would indicate that feruloylquinides have an ED5Q of 0.024 mg/ml. The finding of 0.05 mg/ml for crude feruloylquinides indicates that one or more of the isomeric forms of feruloylquinide produce the predominant opiate receptor binding activity of instant coffee.
TABLE 1. The half-maximal effective dose (EDo-.u-)* of materials derived from, or known to occur in, roasted coffee.
ED50 (mg/ml)
Brewed Arabica Coffees+ 3.0, 3.9 (14.7 14.6)
Brewed Robusta Coffees+ 2.1, 1.8 (7.6 10.8)'
Instant Coffees (Different
Types) 1.1 ± 0.1 (mean ± s.e'.m. ; n-43)
Product of treatment of instant coffee with Amberlite XAD-2 and C18 silica (Fig.l) 0.45
Flash chromatography fractions
(Fig.l)
No. 7 >10
8 0.35
9 0.25
10 0.1
11 0.05
12,rl3 0.1
14,rl5, .16 0.15
1 , ,18 0.2
19, ,20 0.6
- and 5-caffeoylquinides (see text) >10
3,4-dihydroxystyrene, synthesized (Rahn, . & Konig, .A. J. High Resolution Chromatogr. Commun.l, 69-71 (1978)) >10
4-vinylguaiacol,synthesized
(Reichstein, T. Helv.
Chi . Acta 15, 1450-1453(1932) ) 1.2
TABLE LEGEND
* ED-.'s represent the concentration of material required to displace by 50% the binding of 3 H-naloxone in a crude rat brain membrane preparation as described in detail hereinafter. Samples were dissolved in 0.05 M Tris (HCl buffer at pH 7.4 and assayed in triplicate' at 3 to 5 concentrations. ED-, values are determined graphically on log transformed data.
+ Two varieties each of Arabica and Robusta green beans were roasted to 15% weight loss. Each was ground to a particle size ^0.5 mm and 10 g samples were extracted with 10 ml water at 100°C in a single pass expresso coffee maker. Each brew was lyophilized and dry residues weighed and redissolved for assay. ED^-. values represent the concentrations with respect to the mass of dry residue. Due to different extraction percentages for the four varieties (ranging from 16-27%) , the ED=5f) va ues ln green bean mass equivalents are also presented (in brackets) .
Further details of the isolation of opiate receptor-activity material in instant coffee powder, and of the characterisation thereof, and of the synthesis of the compounds of the invention, are set out in the following Examples:
EXAMPLE 1
A. Isolation Scheme (see Figure 1) .
1. An aqueous suspension of instant coffee (2.5 g/100ml) was passed through a column of Amberlite XAD-2 (7 g/g coffee powder) and the column washed with an equal volume of water. Adsorbed material was eluted with 80% aqueous methanol and -the * methanol evaporated _in vacuo. Then residue was adjusted to 20% aqueous methanol.
2. Solution was stirred with reverse phase C18 silica (from Waters SEP-PAK cartridges ) 1 g/10 ml, for at least 10 minutes, filtered, and washed with 20% aqueous methanol until no further colour eluted. Then C18 silica extracted with 60% aqueous methanol (10 ml/g) and filtered solution initially evaporated in vacuo to an aqueous suspension, then, lyophilized to light brown flakes.
3. A column of silica (Merck Kieselgel 60, 230-400 mesh) was prepared for flash chromatography (Still, W.C., ahn, M. & Mitra, A. J. Org. Chem. 43, 2923-2925 (1978) ) with CHC13-CH30H (80:20 v/v) and coffee concentrate applied to the top as a suspension. Volume of developing solvent and size of fractions were as recommended (Still et al, supra) with positive pressure to give a solvent
drop of 1 cm/min. After removal of solvent, each fraction was assessed by an ED^- determination in the opiate receptor binding assay as detailed below. The results are shown in Table 1. Fractions with an ED-- of 0.1 mg/ml or less were combined.
4. Preparative gel permeation chromatography using Waters HLPC instrumentation (model 6000A pump, model U 6 injector, model 450 variable wavelength o detector) and a Waters Ultrastyragel 100A column, was carried out with tetrahydrofuran (THF) as solvent at 1 ml/min. Injections of extract in THF (10 mg/ml) was 100 μl and 0.2 ml fractions collected. Analytical assessment of each fraction was made with 3 μl injections and detection at 300 rim. Most of the UV absorbing material had a retention volume of 6.93 ml and those preparative fractions with a single peak at 6.93 ml, were combined and again reprocessed by preparative GPC as above. After the second purification, the combined fractions were evaporated with N- and dried prior to GC-MS.
Figure 2 shows mass chromatograms of (A) TMS derivatives of instant coffee extract (Fig.l) showing time profiles of total ion current, ions m/z 249 (feruloyl ion), and m/z 566 and (b) TMS derivatives of 4- and 5-caffeoylquinides showing time profiles of total ion current, ion m/z 307 (caffeoyl ion) , and m/z 624 (M+) . Derivatives were prepared by reaction of sample with 100 μl trimethylsilylimidazole (Pierce) and
100 μl dry acetonitrile for 30 min at 60°C in sealed vials. One icrolitre was injected into gas
chromatograph with temperature program 200°C to 300°C at 10°C/min with final hold time of 10 in at 300°C. Carrier gas was helium at 30 ml/min and injection and detector zones were 300°C. The column (2 m x 2 mm ID) was packed with 3% SP2100 on chro osorb W. Detection of the effluent was by mass spectrometry (Finnigan Model 4021) using electron impact ionization at 70 eV and a source temperature of 250°C.
B. Opiate Receptor Binding Assay
The receptor assay system was based on that of Pert and Snyder (Pert, C.B. & Snyder, S.H., Proc. Natu. Acad. Sci. U.S.A. 70, 2243-2247, (1973) ). Male Sprague-Dawley rats were killed by decapitation, and brains minus cerebellum homogenized in 25x vol of 0.05 Tris-HCl, pH 7.4 buffer using a Brinkmarin Polytron on setting 4 for 5 s. The homogenate was centrifuged for 20 min at 18,000 g, and the pellet resuspended in 25x vol buffer. Aliquots (0.5 ml) of this preparation were incubated with 1 nM 3H-naloxone (40 Ci mmol -1; NEN) alone or with various test preparations. Incubations were done in 0.5% BSA and 10% Trasylol for 30 min at
25°C, and terminated by rapid vacuum filtration through Whatman GF/B glass fibre filters pre-wetted with buffer containing 0.5% BSA. Filters were washed with 5 ml buffer, air-dried and added to 10 ml non-aqueous scintillant.
EXAMPLE 2 a. Preparation of quinic-1,3-lactone
Quinic acid in anhydrous DMF (dimethylformamide) was added to DCC (dicyclohexylcarbodiimide) in DMF magnetically stirred at room temperature. Pyridine was
added and after stirring for 30 minutes, the solution went turbid. Stirring was continued for a further two and a half hours.
b. Preparation of acetylferulic acid
Acetylferulic acid was prepared after the method of L.S.Fosdick & A.C.Starke, J.Am.Chem.Soc. 6J2, 3352-5 (1940).
c. Preparation of acetylferuloylquinides
Quinic-1,3-lactone and acetylferulic acid prepared as described above were reacted to form the desired esters.
d. Preparation of Feruloylquinides
Acetylferuloylquinide from the previous preparation was dissolved in methanol and K^CO^ dissolved in aq.methanol was added.
EXAMPLE 3
Using acetylisoferulic acid (prepared previously by J.Pacsu and C.Stieber, Ber. 62B, 2974-9 (1929)), acetylisoferuloylquinides may be prepared exactly as described previously•for acetylferuloylquinides.
Removal of the acetyl group as described above yields the desired isoferuloylquinides.
EXAMPLE 4 Reaction of 4,5-O-isopropylidenequinide (prepared as described by H.O.L.Fischer, Chem.Ber. 5_4, 775-83 (1921) ) with acetyl feruloyl chloride (prepared as described by L.S.Fosdick and A.C.Starke, supra) , yields l-O-acetylferuloyl-4,5-O-isopropylidenequinide. The
hydrolytic removal of the 4,5-O-isopropylidene group from the 1-O-substituted quinide may be performed by known methods (for example, as described by J.D.Elliott, M. Hetmanski, R.D.Stoodley, M.N. Palfreyman, J.C.S.Perkin I, 1782-88 (1981)). The acetyl group may be removed by the method described previously to yield the 1-feruloyl ester of quinic-1,3-lactone.
By analogous methods using acetylisoferuloyl chloride instead of acetylferuloyl chloride, the 1-isoferuloyl ester of quinic-l,3-lactone may be prepared.
EXAMPLE 5
The general procedures of Example 4, may be repeated using 2,2,2-trichloroethoxycarboxy esters as protecting groups on the 1-, or 1- and 5-, hydroxy groups of quinic-1,3—lactone, following 'the methods for synthesis and facile hydrolysis described by T.B.Windolz and D.B.R.Johnston, Tetrahedron Lett. 2555 (1967) .
EXAMPLE 6
Hydrolytic removal of 4,5-O-isopropylidene group from 1-O-acetylferuloyl-4,5-0-isopropylidenequinide (described as an intermediate in the synthesis of 1-feruloylquinic acid by A.Zane and S.H.Wender, Chem.S Ind. 1034-5 (1965)) by the method of Elliott et al; supra, followed by removal of the acetyl group by the method described previously yields the 1-feruloyl ester of quinic-l,3-lactone.
Claims
1. A compound having opiate receptor binding activity of the general formula I:
wherein one of the R-, R2 and R_ groups represents a feruloyl or isoferuloyl group of the formula II or III, respectively:
and
and the other R, , R2 and R~ represent hydrogen.
2. A compound of the general formula I defined in claim 1, in substantially pure form.
3. A process for the preparation of a compound of the general formula I as defined in claim 1, which comprises extraction from instant coffee or from coffee beans which have been roasted, ground and extracted with water, said extraction including the steps of adsorption on an ion exchange resin, followed by chromatography to isolate fractions having the desired activity.
4. A process for the preparation of a compound of the general formula I as defined in claim 1, which comprises pyrolysis of a corresponding feruloylquinic acid of the general formula IV:
5. A process for the preparation of a compound of the general formula I as defined in claim 1, which process comprises the reaction of quinic-l,3-lactone of the formula V:
wherein each R. separately represents H or a removable hydroxy protecting group, with a ferulic or isoferulic acid of the formula VI or VII, respectively:
wherein R. is an acetyl or other hydroxy protecting group, or a reactive derivative thereof, followed by removal of the group R. and, if necessary, any hydroxy
1 4 protecting group R .
6. A process as defined in claim 5, which comprises the reaction of quinic-1,3-lactone of the formula
with the hydroxyls on carbons 4 and 5 blocked with an isopropylidene group (formula VA) , or the hydroxyl on carbon 1 protected with a 2,2,2-trichloroethoxy carboxy ester (formula VB) or both hydroxyls 1 and 5 similarly esterified (formula VC) :
with a feruloyl or isoferuloyl chloride of formula VIII or IX respectively:
wherein R4 is an acetyl or other hydroxy protecting group, followed by removal of the group R. and the protecting isopropylidene or 2,2,2-trichloroethoxy carbody groups.
7. A pharmaceutical composition for the treatment of the toxic effects of opiate narcotic analgesics, comprising a compound of the general formula I as defined in claim 1, together with one or more pharmaceutically acceptable carriers or diluents therefor.
8. A method of treatment of the toxic effects of opiate narcotic analgesics, which method comprises administration of an effective amount of a compound of the general formula I as defined in claim 1, or of a pharmaceutical composition containing a said compound.
9. Use of a compound of the general formula I as defined in claim 1, for the treatment of the toxic effects of opiate narcotic analgesics, or for the manufacture of a pharmaceutical composition for the treatment of the toxic effects of opiate narcotic analgesics.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPG6761 | 1984-08-24 | ||
AU676184 | 1984-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1986001508A1 true WO1986001508A1 (en) | 1986-03-13 |
Family
ID=3697344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1985/000200 WO1986001508A1 (en) | 1984-08-24 | 1985-08-23 | Opiate antagonists |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0190296A1 (en) |
WO (1) | WO1986001508A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0581980A1 (en) * | 1992-08-03 | 1994-02-09 | Societe Des Produits Nestle S.A. | 3- and/or 4-substituted derivatives of quinic acid and process to prepare 3- and/or 4-substituted derivatives of quinic acid |
EP0581979A1 (en) * | 1992-08-03 | 1994-02-09 | Societe Des Produits Nestle S.A. | Quinic acid derivatives and process to prepare quinic acid derivatives |
WO2002060462A3 (en) * | 2001-01-30 | 2002-12-19 | Laboratorios Biosintetica Ltda | Waay to obtain a extract with antidepressant and opioid antagonists properties and pharmaceutical products obtained from it |
US6693128B2 (en) | 2001-05-11 | 2004-02-17 | Vanderbilt University | Substituted dicinnamoylquinides and their use in augmentation of adenonsine function |
WO2007002112A3 (en) * | 2005-06-20 | 2007-02-15 | Procter & Gamble | Processes for isolating bitter compounds for use in food and beverage products |
CN108003027A (en) * | 2017-12-25 | 2018-05-08 | 北京微医智慧信息技术有限责任公司 | 1-O- caffeoylquinic acids, its derivative, preparation method and its usage |
-
1985
- 1985-08-23 EP EP19850904076 patent/EP0190296A1/en not_active Withdrawn
- 1985-08-23 WO PCT/AU1985/000200 patent/WO1986001508A1/en unknown
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0581980A1 (en) * | 1992-08-03 | 1994-02-09 | Societe Des Produits Nestle S.A. | 3- and/or 4-substituted derivatives of quinic acid and process to prepare 3- and/or 4-substituted derivatives of quinic acid |
EP0581979A1 (en) * | 1992-08-03 | 1994-02-09 | Societe Des Produits Nestle S.A. | Quinic acid derivatives and process to prepare quinic acid derivatives |
US5395950A (en) * | 1992-08-03 | 1995-03-07 | Nestec S.A. | Production of quinic acid derivatives |
US5401858A (en) * | 1992-08-03 | 1995-03-28 | Nestec S.A. | Preparation of quinic acid derivatives |
AU662231B2 (en) * | 1992-08-03 | 1995-08-24 | Societe Des Produits Nestle S.A. | 3- and/or 4-substituted derivatives of quinic acid and a process for the production of 3- and/or 4-substituted derivatives of quinic acid |
AU662430B2 (en) * | 1992-08-03 | 1995-08-31 | Societe Des Produits Nestle S.A. | Derivatives of quinic acid and a process for their production |
WO2002060462A3 (en) * | 2001-01-30 | 2002-12-19 | Laboratorios Biosintetica Ltda | Waay to obtain a extract with antidepressant and opioid antagonists properties and pharmaceutical products obtained from it |
US6693128B2 (en) | 2001-05-11 | 2004-02-17 | Vanderbilt University | Substituted dicinnamoylquinides and their use in augmentation of adenonsine function |
WO2007002112A3 (en) * | 2005-06-20 | 2007-02-15 | Procter & Gamble | Processes for isolating bitter compounds for use in food and beverage products |
JP2008543336A (en) * | 2005-06-20 | 2008-12-04 | ザ プロクター アンド ギャンブル カンパニー | Method for isolating bitter compounds for use in food and beverage products |
CN108003027A (en) * | 2017-12-25 | 2018-05-08 | 北京微医智慧信息技术有限责任公司 | 1-O- caffeoylquinic acids, its derivative, preparation method and its usage |
WO2019128113A1 (en) * | 2017-12-25 | 2019-07-04 | 北京微医智慧信息技术有限责任公司 | 1-o-caffeoylquinic acid, derivative thereof, preparation method thereof, and application thereof |
CN108003027B (en) * | 2017-12-25 | 2021-07-06 | 北京微医智慧信息技术有限责任公司 | 1-O-caffeoylquinic acid, its derivative, preparation method and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0190296A1 (en) | 1986-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ghedira et al. | Four cyclopeptide alkaloids from Zizyphus lotus | |
Hahn et al. | Hydroxycinnamic acid derivatives, caffeoylmalic and new caffeoylaldonic acid esters, from chelidonium majus*, 1 | |
Murata et al. | Hydroxycinnamic Acid Derivatives and p-Coumaroyl-(L)-trypropban, A NovelHydroxycinnamic Acid Derivative, from Coffee Beans | |
WO1986001508A1 (en) | Opiate antagonists | |
Hsieh et al. | The constituents of Cananga odorata | |
Rasheed et al. | Hirsutine: A new alkaloid from Cocculus hirsutus | |
TAKEDA et al. | Studies on the bacterial gall of Myrica rubra: isolation of a new [7, 0]-metacyclophan from the gall and DL-β-phenyllactic acid from the culture of gall-forming bacteria | |
Burkhardt et al. | Terpene hydrocarbons in Pimpinella anisum L. | |
Ozawa et al. | Elucidation of the partial structure of polymeric thearubigins from black tea by chemical degradation | |
Pelletier et al. | Alkaloids of Delphinium barbeyi | |
Chimichi et al. | Complete assignment of the 1H and 13C NMR spectra of secoisolariciresinol diglucoside, a mammalian lignan precursor isolated from Linum usitatissimum | |
Hirai et al. | Isolation and structure elucidation of fecapentaenes-12, potent mutagens from human feces | |
de Araújo-Júnior et al. | Alkaloids and diterpenes from Croton moritibensis | |
Ferris et al. | Lythraceae alkaloids. VIII. Structure and stereochemistry of the biphenyl ether alkaloids from Decodon verticillatus | |
Lahloub et al. | Ehrenoside, a New Phenylpropanoid Glycoside from Veronica bellidioides1 | |
Lavie et al. | Trechonolide A, a new withanolide type from Trechonaetes laciniata | |
Chi et al. | Monoterpene alkaloids from Incarvillea sinensis. VI. absolute stereochemistry of incarvilline and structure of a new alkaloid, hydroxyincarvilline | |
Costa et al. | Indole alkaloids from the roots of an African plant Securidaca longipedunculata. I. Isolation by column chromatography and preliminary structural characterization by mass spectrometry | |
Pummangura et al. | Cactus alkaloids. XLIX. New trace alkaloids (dehydrosalsolidine and heliamine) from the saguaro, Carnegiea gigantea, and confirmation by Mikes (MS/MS) | |
US4137231A (en) | Process for the isolation of 2-hydroxymethyl-3,4,5-trihydroxypiperidine from plant material | |
Férnandez-Gadea et al. | Isoeriocephalin and 20-deacetyleriocephalin, neoclerodane diterpenoids from Teucrium lanigerum | |
Asres et al. | Two novel minor alkaloids from Ethiopian Calpurnia aurea ssp. Aurea | |
Casale et al. | Alkaloid content of the seeds from Erythroxylum Coca var. Coca | |
Moore et al. | Lesser Alkaloids of Cocaine-Bearing Plants. Part I: Nicotinoyl-, 2′-Pyrroloyl, and 2′-and 3′-Furanoylecgonine Methyl Ester—Isolation and Mass Spectral Characterization of Four New Alkaloids of South American Erythroxylum coca Var. coca | |
Weckerle et al. | Linalool disaccharides as flavour precursors from green coffee beans (Coffea arabica) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): CH DE FR GB IT NL SE |